Abstract: The present invention relates to a Siphoviridae bacteriophage Str-INP-1 (Accession NO: KCTC 12687BP) that is isolated from the nature and can kill specifically Streptococcus iniae cells, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1, and a method for preventing and treating the infections of Streptococcus iniae using the composition comprising said bacteriophage as an active ingredient.

Abstract: Certain techniques are provided for triggering events based on detecting changes in CV features, such as edges, corners etc., by generating computed results based on sensor readings. Yet other techniques also provided for detecting CV features once an event is detecting based on a change in a sensor reading for a sensor element. In certain aspects, the event detection logic and the feature calculation CV vision operations may be performed, individually, or in combination in circuitry on a sensor or in software/firmware on a computing device.

Abstract: The present invention relates to heme iron not derived from porcine blood and a method of preparing the same, and more particularly to a method of biologically preparing heme iron not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient.

Abstract: A deposition mask includes: a plurality of sub-masks through which deposition material passes to a base layer to form a deposition layer defining a hole therein, each of the sub-masks including: an aperture through which the deposition material passes to the base layer, a total planar area of the aperture corresponding to less than a total planar area of the deposition layer, and a masking surface at which the deposition material does not pass through the sub-mask, the masking surface including a hole-forming portion of which a total planar area thereof corresponds to a total planar area of the hole defined in the deposition layer. The hole-forming portions of the sub-masks have a same shape and planar area as each other, and within each sub-mask, the shape of the hole-forming portion is nested within a shape of the aperture.

Abstract: An automotive display device on which an image may be displayed, the automotive display device being for a vehicle interior, the automotive display device including an automotive frame, at least part of the automotive frame being bendable; and a bending controller to control bending of the automotive frame.

Abstract: The present invention relates to: Myoviridae bacteriophage Pas-MUP-1 (accession number KCTC 12706BP) which has the capability to specifically destroy Pasteurella multocida, is characterized by having a genome represented by SEQ ID NO: 1, and is isolated from nature; and a method for preventing and treating Pasteurella multocida infections, using a composition containing bacteriophage Pas-MUP-1 as an active ingredient.

Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by means of the pharmaceutical composition.

Abstract: The present invention relates to Siphoviridae bacteriophage Clo-PEP-2 (accession number KCTC 13185BP), separated from nature, which is capable of killing Clostridium perfringens and has a genome expressed by sequence number 1 and a method for preventing or treating diseases, induced by Clostridium perfringens, by means of a composition comprising the Siphoviridae bacteriophage Clo-PEP-2 as an active ingredient.

Abstract: The present invention relates to an antibacterial protein EFAL-2 derived from bacteriophage Ent-FAP-4 (deposition number KCTC 12854BP), a pharmaceutical composition including the same as an active ingredient, and a method for preventing or treating diseases caused by Enterococcus faecium by using the pharmaceutical composition, the antibacterial protein EFAL-2 being characterized by having the ability capable of killing Enterococcus faecium and having an amino acid sequence represented by SEQ ID NO: 2.

Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-4 (accession number: KCTC 13166BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-4 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-4 as an active ingredient.

Abstract: The present invention relates to Podoviridae bacteriophage Pse-AEP-3 (accession number: KCTC 13165BP) isolated from nature, the Podoviridae bacteriophage Pse-AEP-3 having the capability to specifically kill Pseudomonas aeruginosa and having a genome represented by SEQ ID NO: 1, and a method for preventing or treating diseases induced by Pseudomonas aeruginosa by using a composition containing the Podoviridae bacteriophage Pse-AEP-3 as an active ingredient.

Abstract: The present invention relates to heme iron not derived from porcine blood and a method of preparing the same, and more particularly to a method of biologically preparing heme iron not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient.

Abstract: The present invention relates to heme iron not derived from porcine blood and a method of preparing the same, and more particularly to a method of chemically preparing heme iron not derived from porcine blood, a method of preparing a salt thereof, and an iron supplement containing the salt thus prepared as an active ingredient.

Abstract: The present invention relates to Myoviridae bacteriophage Vib-PAP-4 (Accession No. KCTC 13168BP), isolated from nature, which possesses ability to specifically kill Vibrio parahaemolyticus bacteria and has the genome represented by SEQ ID No: 1, and a method for preventing infection of Vibrio parahaemolyticus bacteria and treating infection of Vibrio parahaemolyticus baceteria, using a composition containing the bacteriophage as an effective ingredient.

Abstract: The present invention relates to a Myoviridae bacteriophage ESC-COP-7 (accession number KCTC 13130BP) isolated from nature, and a method for preventing and treating infections from pathogenic Escherichia coli by means of a composition containing the Myoviridae bacteriophage ESC-COP-7 as an active ingredient, the Myoviridae bacteriophage ESC-COP-7 being characterized by having the capability to specifically kill Escherichia coli, and genome expressed by the SEQ ID 1.

Abstract: The present invention relates to Myoviridae bacteriophage Esc-COP-9 (Accession No. KCTC 13131BP) isolated from nature, which has a genome represented by SEQ ID NO: 1 and an ability to specifically kill E.coli, and a method for preventing and treating pathogenic E. coli infections by using a composition comprising the same as an active ingredient.

Abstract: A positive active material for a rechargeable lithium battery and a rechargeable lithium battery including the same are disclosed. The positive active material includes a core including a lithium intercalation compound and a crystalline coating compound on a surface of the core and including a crystalline aluminum hydroxide, a crystalline aluminum oxyhydroxide, or a combination thereof.

Abstract: A method of treating staphylococcal infections includes administering to a subject an effective amount of an antibacterial composition having a broad bactericidal activity. The antibacterial composition includes a first antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 1 and/or a second antibacterial protein consisting of the amino acid sequence as set forth in SEQ. ID. NO: 2.

Abstract: The present invention relates to a novel compound and a composition for the prevention, alleviation or treatment of fibrosis or non-alcoholic steatohepatitis, which contains the compound as an active ingredient, and more particularly to a novel compound of Formula 1, which has an excellent effect on the prevention, alleviation or treatment of fibrosis, and to a composition for the prevention, alleviation or treatment of fibrosis or non-alcoholic steatohepatitis, which contains the compound as an active ingredient. The novel compound can regulate the activation of EMT (epithelial-mesenchymal transition) by effectively regulating the expression of snail and vimentin which are regulators of EMT, and thus can effectively prevent, alleviate or treat fibrosis. Furthermore, the novel compound has very good pharmacokinetics. In addition, the novel compound of the present invention can effectively inhibit fibrosis of liver cells, and thus can also effectively alleviate or treat non-alcoholic steatohepatitis.

Abstract: A compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof: wherein R1 is a substituted or unsubstituted C1-5 linear or branched alkyl, a C5-6 cycloalkyl, a C5-6 cycloalkyl containing at least one heteroatom selected from among O and N, a substituted or unsubstituted C6-12 aryl, or a C5-6 heteroaryl containing at least one heteroatom selected from among O and N; R2 is hydrogen, ethyl, acetyl, acetoxy, carboxy, benzoyloxy or 3,4,5-trihydroxybenzoyloxy; and R3 to R5 are each independently hydrogen, hydroxyl, methyl, methoxy, acetoxy, carboxy or benzoyloxy.